+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Infantile Spasms Therapeutics Market by Therapeutic Class, Distribution Channel, Route of Administration, End User - Global Forecast to 2030- Product Image
Infantile Spasms Therapeutics Market by Therapeutic Class, Distribution Channel, Route of Administration, End User - Global Forecast to 2030- Product Image
Sale

Infantile Spasms Therapeutics Market by Therapeutic Class, Distribution Channel, Route of Administration, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 194 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 4904865
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Infantile Spasms Therapeutics Market grew from USD 406.01 million in 2024 to USD 432.78 million in 2025. It is expected to continue growing at a CAGR of 6.47%, reaching USD 591.63 million by 2030.

A Comprehensive Overview of the Infantile Spasms Therapeutic Landscape

Infantile spasms represent one of the most challenging pediatric epileptic disorders, characterized by sudden, debilitating seizure episodes and profound developmental impacts. Early intervention remains critical, as delayed treatment often leads to irreversible neurological damage and long-term cognitive deficits. This executive summary synthesizes the current landscape of therapeutic approaches, highlighting key innovations, regulatory developments, and market drivers that define the field today.

Our analysis examines both established and emerging therapeutic classes, evaluates the evolving distribution channels that deliver these critical treatments, and delineates the diverse administration routes that dictate clinical adoption. By integrating regional dynamics and the latest policy shifts, we offer an authoritative overview designed to guide decision-makers through the complexities of the infantile spasms market. Whether you are a pharmaceutical executive, investor, or healthcare strategist, this introduction sets the stage for a deeper exploration of transformative trends and actionable insights.

Mapping the Major Disruptions Reshaping the Market

Over the past several years, the infantile spasms arena has witnessed transformative shifts that go beyond incremental improvements. Novel molecular targets identified through genomic profiling have spurred a wave of precision-oriented trials, pushing beyond traditional anti-epileptic approaches. In parallel, advances in neuroimaging and digital seizure monitoring have enriched our understanding of treatment response dynamics, enabling more personalized dosing regimens and optimized therapeutic windows.

Regulatory agencies have also adapted to the urgency of early-onset epilepsies, deploying accelerated approval pathways and incentivizing pediatric rare disease research. These policy adjustments have shortened development timelines and encouraged strategic alliances between biotechs and established pharma. Meanwhile, the proliferation of telehealth platforms has enhanced follow-up care, boosting adherence and enabling real-world data collection that continually refines clinical best practices. Together, these converging factors are fundamentally reshaping both the speed and scope of progress in infantile spasms therapeutics.

Assessing the Repercussions of New US Tariff Measures

The introduction of new United States tariffs on pharmaceutical imports in 2025 has injected additional complexity into the supply chain for infantile spasms treatments. Raw materials integral to the synthesis of active pharmaceutical ingredients, such as those used in both anti-epileptic and hormonal therapies, now face elevated cost pressures. Manufacturers are compelled to reassess sourcing strategies, with some exploring domestic production partnerships to mitigate import duties and ensure uninterrupted availability for vulnerable infant populations.

Beyond direct cost implications, the tariff landscape has influenced pricing negotiations with payers, prompting more rigorous reimbursement assessments. Companies holding proprietary formulations are evaluating alternative formulations and localized manufacturing hubs to preserve margin while meeting regulatory standards. The net effect is a strategic recalibration across the industry, where supply chain resilience and tariff-aware procurement have become core elements of market readiness and long-term access planning.

In-Depth Analysis of Market Segmentation Dynamics

Our segmentation analysis reveals that therapeutic class remains a primary driver of competitive differentiation, with anti-epileptic drugs anchored by vigabatrin holding a prominent market share and hormonal therapies led by adrenocorticotropic hormone alongside corticosteroid regimens carving out crucial treatment niches. These options address distinct mechanistic pathways, and their positioning continues to evolve as clinicians weigh efficacy, safety, and long-term developmental outcomes.

Distribution channels reflect the growing complexity of pharmaceutical access. Hospital pharmacies dominate initial dispensing, particularly for injectable formulations administered under medical supervision, while online pharmacy solutions have gained traction for ongoing supply continuity. Retail pharmacies remain integral for refill accessibility and patient convenience, underpinning a hybrid distribution model that balances clinical oversight with patient-centered flexibility.

Route of administration further refines the patient journey. Injectable therapies, delivered intramuscularly or intravenously, enable rapid onset of action during critical seizure control phases, whereas oral solutions and tablets facilitate maintenance therapy and outpatient management. Each route demands tailored educational materials and adherence strategies to optimize real-world outcomes.

End-user segmentation underscores the diverse care settings engaged in infantile spasms management. Home care services provide essential support for caregivers, allowing for supervised administration in familiar environments. Hospitals continue to lead in acute care and diagnostic evaluation, while specialized clinics bring together multidisciplinary teams for complex cases and long-term developmental monitoring.

Regional Market Patterns Revealed

Regional differences shape investment priorities and market penetration strategies for infantile spasms therapies. In the Americas, advanced regulatory frameworks and robust reimbursement policies bolster rapid uptake of both established and novel treatments, driving competitive launches and expanded access programs. Growth here is underpinned by strong advocacy networks and early adoption of telemedicine innovations that facilitate comprehensive patient monitoring.

In Europe, Middle East & Africa, the regulatory environment varies significantly across jurisdictions, resulting in a mosaic of approval timelines and reimbursement levels. While Western Europe often mirrors American pace in adopting new therapies, emerging markets in the region exhibit slower uptake due to budget constraints and supply chain hurdles. Strategic partnerships with local distributors and tailored health-economic value models are proving critical to overcoming these barriers.

Asia-Pacific presents a vibrant landscape of high unmet need coupled with rapidly evolving healthcare infrastructure. Countries such as Japan and Australia have established pediatric rare disease frameworks, accelerating access to advanced hormonal and anti-epileptic therapies. In contrast, markets across Southeast Asia and India are characterized by cost-sensitive procurement and a growing emphasis on generics, prompting global and domestic players to adapt pricing strategies and patient support programs.

Leading Players Driving Therapeutic Innovation

Leading players in the infantile spasms domain are distinguished by their investment in specialized formulations and strategic pipeline expansions. Teva’s experience with generic vigabatrin provides a cost-effective benchmark for standard epilepsy management, while Ovid Therapeutics drives innovation with its development of ganaxolone, targeting novel receptor pathways. These contrasting approaches highlight the balance between established, lower-cost options and the premium positioning of next-generation therapies.

Mallinckrodt’s repository corticotropin formulations maintain a strong presence in hormonal treatment, leveraged through comprehensive patient support services and targeted education initiatives. Simultaneously, Lundbeck’s broader epilepsy portfolio and collaborative trials with academic centers underscore the value of research partnerships in advancing treatment algorithms. Together, these companies exemplify a competitive landscape where generic economies, proprietary innovations, and strategic alliances converge to shape patient care.

Strategic Recommendations to Secure Market Leadership

To thrive in this dynamic environment, industry leaders should prioritize integrated R&D investments that bridge molecular innovation with real-world clinical insights. Cultivating partnerships with genetic research institutions can accelerate the identification of biomarkers predictive of treatment response, enhancing both trial design and personalized care pathways. Concurrently, optimizing supply chains in light of new tariff regimes will require collaborative forecasting with key suppliers and exploration of regional production hubs to safeguard uninterrupted access.

Engagement with payers and health authorities is equally critical; demonstrating product value through health outcomes data and cost-effectiveness analyses will facilitate more favorable reimbursement decisions. Companies should deploy tailored educational programs for neurologists and pediatricians, emphasizing the nuanced benefits and administration protocols of both established and emerging therapies. Finally, leveraging digital health platforms for patient monitoring and adherence support can drive superior long-term outcomes and foster robust post-launch evidence generation.

Rigorous Methodology Underpinning Our Insights

This report synthesizes insights derived from a multifaceted research framework. Primary research included in-depth interviews with key opinion leaders, clinical specialists, and senior executives across pharmaceutical manufacturers and healthcare providers. Secondary sources encompassed peer-reviewed journals, conference proceedings, regulatory filings, and white papers from global health authorities.

Data validation involved cross-referencing findings with public databases and corroborating quantitative trends through multiple independent sources. Qualitative insights were systematically analyzed to identify recurring themes in therapeutic innovation, policy impacts, and patient care pathways. This rigorous methodology ensures the reliability and relevance of the strategic guidance presented throughout this executive summary.

Concluding Perspectives on Future Trajectories

The convergence of scientific breakthroughs, policy evolution, and shifting market forces underscores the accelerating pace of change in infantile spasms therapeutics. As genetic profiling and digital health tools mature, the potential to deliver highly targeted interventions will redefine treatment paradigms and improve long-term outcomes for affected infants.

Industry stakeholders must remain agile, continuously aligning investment priorities with emerging data and regulatory incentives. By integrating segmentation nuances, regional dynamics, and the implications of new tariff measures, organizations can craft resilient strategies that address both global opportunities and localized challenges. This conclusion reinforces the imperative for strategic foresight and collaborative innovation in shaping the future of infantile spasms care.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Therapeutic Class
    • Anti-Epileptic Drugs
      • Vigabatrin
    • Hormonal Therapies
      • Adrenocorticotropic Hormone
      • Corticosteroids
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • Route Of Administration
    • Injectable
      • Intramuscular
      • Intravenous
    • Oral
      • Solution
      • Tablet
  • End User
    • Home Care
    • Hospitals
    • Specialized Clinics
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Mallinckrodt plc
  • UCB Pharma SA
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Sandoz International GmbH
  • Pfizer Inc.
  • Hikma Pharmaceuticals PLC
  • Accord Healthcare, Inc.
  • Camber Pharmaceuticals, Inc.
  • Amneal Pharmaceuticals, Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Infantile Spasms Therapeutics Market, by Therapeutic Class
8.1. Introduction
8.2. Anti-Epileptic Drugs
8.2.1. Vigabatrin
8.3. Hormonal Therapies
8.3.1. Adrenocorticotropic Hormone
8.3.2. Corticosteroids
9. Infantile Spasms Therapeutics Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacies
9.3. Online Pharmacies
9.4. Retail Pharmacies
10. Infantile Spasms Therapeutics Market, by Route of Administration
10.1. Introduction
10.2. Injectable
10.2.1. Intramuscular
10.2.2. Intravenous
10.3. Oral
10.3.1. Solution
10.3.2. Tablet
11. Infantile Spasms Therapeutics Market, by End User
11.1. Introduction
11.2. Home Care
11.3. Hospitals
11.4. Specialized Clinics
12. Americas Infantile Spasms Therapeutics Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Infantile Spasms Therapeutics Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Infantile Spasms Therapeutics Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Mallinckrodt plc
15.3.2. UCB Pharma SA
15.3.3. Teva Pharmaceutical Industries Ltd.
15.3.4. Viatris Inc.
15.3.5. Sandoz International GmbH
15.3.6. Pfizer Inc.
15.3.7. Hikma Pharmaceuticals PLC
15.3.8. Accord Healthcare, Inc.
15.3.9. Camber Pharmaceuticals, Inc.
15.3.10. Amneal Pharmaceuticals, Inc.
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. INFANTILE SPASMS THERAPEUTICS MARKET MULTI-CURRENCY
FIGURE 2. INFANTILE SPASMS THERAPEUTICS MARKET MULTI-LANGUAGE
FIGURE 3. INFANTILE SPASMS THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. INFANTILE SPASMS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. INFANTILE SPASMS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. INFANTILE SPASMS THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTI-EPILEPTIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY VIGABATRIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTI-EPILEPTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ADRENOCORTICOTROPIC HORMONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY SOLUTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY SPECIALIZED CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTI-EPILEPTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 40. UNITED STATES INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 41. UNITED STATES INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTI-EPILEPTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 42. UNITED STATES INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 49. CANADA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 50. CANADA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTI-EPILEPTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 51. CANADA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 52. CANADA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 53. CANADA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 54. CANADA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 55. CANADA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 56. CANADA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 57. MEXICO INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 58. MEXICO INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTI-EPILEPTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 59. MEXICO INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 60. MEXICO INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 61. MEXICO INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 62. MEXICO INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 63. MEXICO INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 64. MEXICO INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 65. BRAZIL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 66. BRAZIL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTI-EPILEPTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 67. BRAZIL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 68. BRAZIL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 69. BRAZIL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 70. BRAZIL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 71. BRAZIL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 72. BRAZIL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 73. ARGENTINA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 74. ARGENTINA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTI-EPILEPTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 75. ARGENTINA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 76. ARGENTINA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 77. ARGENTINA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 78. ARGENTINA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 79. ARGENTINA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 80. ARGENTINA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 82. EUROPE, MIDDLE EAST & AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTI-EPILEPTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 83. EUROPE, MIDDLE EAST & AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 84. EUROPE, MIDDLE EAST & AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 85. EUROPE, MIDDLE EAST & AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 86. EUROPE, MIDDLE EAST & AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 87. EUROPE, MIDDLE EAST & AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 88. EUROPE, MIDDLE EAST & AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 89. EUROPE, MIDDLE EAST & AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 90. UNITED KINGDOM INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 91. UNITED KINGDOM INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTI-EPILEPTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 92. UNITED KINGDOM INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 93. UNITED KINGDOM INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 94. UNITED KINGDOM INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 95. UNITED KINGDOM INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 96. UNITED KINGDOM INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 97. UNITED KINGDOM INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 98. GERMANY INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 99. GERMANY INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTI-EPILEPTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 100. GERMANY INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 101. GERMANY INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 102. GERMANY INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 103. GERMANY INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 104. GERMANY INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 105. GERMANY INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 106. FRANCE INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 107. FRANCE INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTI-EPILEPTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 108. FRANCE INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 109. FRANCE INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 110. FRANCE INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 111. FRANCE INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 112. FRANCE INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 113. FRANCE INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 114. RUSSIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 115. RUSSIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTI-EPILEPTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 116. RUSSIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 117. RUSSIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 118. RUSSIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 119. RUSSIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 120. RUSSIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 121. RUSSIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 122. ITALY INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 123. ITALY INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTI-EPILEPTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 124. ITALY INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 125. ITALY INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 126. ITALY INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 127. ITALY INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 128. ITALY INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 129. ITALY INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 130. SPAIN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 131. SPAIN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTI-EPILEPTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 132. SPAIN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 133. SPAIN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 134. SPAIN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 135. SPAIN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 136. SPAIN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 137. SPAIN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 138. UNITED ARAB EMIRATES INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 139. UNITED ARAB EMIRATES INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTI-EPILEPTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 140. UNITED ARAB EMIRATES INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 141. UNITED ARAB EMIRATES INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 142. UNITED ARAB EMIRATES INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 143. UNITED ARAB EMIRATES INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 144. UNITED ARAB EMIRATES INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 145. UNITED ARAB EMIRATES INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 146. SAUDI ARABIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 147. SAUDI ARABIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTI-EPILEPTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 148. SAUDI ARABIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 149. SAUDI ARABIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 150. SAUDI ARABIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 151. SAUDI ARABIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 152. SAUDI ARABIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 153. SAUDI ARABIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 154. SOUTH AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 155. SOUTH AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTI-EPILEPTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 156. SOUTH AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 157. SOUTH AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 158. SOUTH AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 159. SOUTH AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 160. SOUTH AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 161. SOUTH AFRICA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 162. DENMARK INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 163. DENMARK INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTI-EPILEPTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 164. DENMARK INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 165. DENMARK INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 166. DENMARK INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 167. DENMARK INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 168. DENMARK INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 169. DENMARK INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 170. NETHERLANDS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 171. NETHERLANDS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTI-EPILEPTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 172. NETHERLANDS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 173. NETHERLANDS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 174. NETHERLANDS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 175. NETHERLANDS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 176. NETHERLANDS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 177. NETHERLANDS INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 178. QATAR INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 179. QATAR INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTI-EPILEPTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 180. QATAR INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 181. QATAR INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 182. QATAR INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 183. QATAR INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 184. QATAR INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 185. QATAR INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 186. FINLAND INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 187. FINLAND INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTI-EPILEPTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 188. FINLAND INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 189. FINLAND INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 190. FINLAND INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 191. FINLAND INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 192. FINLAND INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 193. FINLAND INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 194. SWEDEN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 195. SWEDEN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTI-EPILEPTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 196. SWEDEN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 197. SWEDEN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 198. SWEDEN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 199. SWEDEN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 200. SWEDEN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 201. SWEDEN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 202. NIGERIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 203. NIGERIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTI-EPILEPTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 204. NIGERIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 205. NIGERIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 206. NIGERIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 207. NIGERIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 208. NIGERIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 209. NIGERIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 210. EGYPT INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 211. EGYPT INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTI-EPILEPTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 212. EGYPT INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 213. EGYPT INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 214. EGYPT INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 215. EGYPT INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 216. EGYPT INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 217. EGYPT INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 218. TURKEY INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 219. TURKEY INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTI-EPILEPTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 220. TURKEY INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 221. TURKEY INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 222. TURKEY INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 223. TURKEY INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 224. TURKEY INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 225. TURKEY INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 226. ISRAEL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 227. ISRAEL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTI-EPILEPTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 228. ISRAEL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 229. ISRAEL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 230. ISRAEL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 231. ISRAEL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 232. ISRAEL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 233. ISRAEL INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 234. NORWAY INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 235. NORWAY INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTI-EPILEPTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 236. NORWAY INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 237. NORWAY INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 238. NORWAY INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 239. NORWAY INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 240. NORWAY INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 241. NORWAY INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 242. POLAND INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 243. POLAND INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTI-EPILEPTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 244. POLAND INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 245. POLAND INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 246. POLAND INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 247. POLAND INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 248. POLAND INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 249. POLAND INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 250. SWITZERLAND INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 251. SWITZERLAND INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTI-EPILEPTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 252. SWITZERLAND INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 253. SWITZERLAND INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 254. SWITZERLAND INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 255. SWITZERLAND INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 256. SWITZERLAND INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 257. SWITZERLAND INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 258. ASIA-PACIFIC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 259. ASIA-PACIFIC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTI-EPILEPTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 260. ASIA-PACIFIC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 261. ASIA-PACIFIC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 262. ASIA-PACIFIC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 263. ASIA-PACIFIC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 264. ASIA-PACIFIC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 265. ASIA-PACIFIC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 266. ASIA-PACIFIC INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 267. CHINA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 268. CHINA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTI-EPILEPTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 269. CHINA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 270. CHINA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 271. CHINA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 272. CHINA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 273. CHINA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 274. CHINA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 275. INDIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 276. INDIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTI-EPILEPTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 277. INDIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 278. INDIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 279. INDIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 280. INDIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 281. INDIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 282. INDIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 283. JAPAN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 284. JAPAN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTI-EPILEPTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 285. JAPAN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 286. JAPAN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 287. JAPAN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 288. JAPAN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 289. JAPAN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 290. JAPAN INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 291. AUSTRALIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 292. AUSTRALIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTI-EPILEPTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 293. AUSTRALIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 294. AUSTRALIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 295. AUSTRALIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 296. AUSTRALIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 297. AUSTRALIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 298. AUSTRALIA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 299. SOUTH KOREA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 300. SOUTH KOREA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ANTI-EPILEPTIC DRUGS, 2018-2030 (USD MILLION)
TABLE 301. SOUTH KOREA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY HORMONAL THERAPIES, 2018-2030 (USD MILLION)
TABLE 302. SOUTH KOREA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 303. SOUTH KOREA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 304. SOUTH KOREA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 305. SOUTH KOREA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 306. SOUTH KOREA INFANTILE SPASMS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2

Companies Mentioned

The companies profiled in this Infantile Spasms Therapeutics market report include:
  • Mallinckrodt plc
  • UCB Pharma SA
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Sandoz International GmbH
  • Pfizer Inc.
  • Hikma Pharmaceuticals PLC
  • Accord Healthcare, Inc.
  • Camber Pharmaceuticals, Inc.
  • Amneal Pharmaceuticals, Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages194
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 432.78 Million
Forecasted Market Value ( USD ) by 2030 $ 591.63 Million
Compound Annual Growth Rate6.4%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Infantile Spasms Therapeutics Market by Therapeutic Class, Drug Type, Dosage, Route of Administration, Distribution Channel, End User, and Region 2025-2033 - Product Image

Infantile Spasms Therapeutics Market by Therapeutic Class, Drug Type, Dosage, Route of Administration, Distribution Channel, End User, and Region 2025-2033

  • Report
  • 128 Pages
  • Global
From
Infantile Spasms Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Infantile Spasms Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 183 Pages
  • Global
From
Infantile Spasms Therapeutics Market: Global Opportunity Analysis and Industry Forecast, 2024-2033 - Product Image

Infantile Spasms Therapeutics Market: Global Opportunity Analysis and Industry Forecast, 2024-2033

  • Report
  • 260 Pages
  • Global
From
Infantile Spasm - Pipeline Insight, 2025 - Product Image

Infantile Spasm - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
Infantile Spasm - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Infantile Spasm - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From

About the Market

Infantile Spasm (IS) is a rare neurological disorder that affects infants and young children. It is characterized by sudden, brief, and repetitive muscle contractions, usually in the form of jerking movements. Treatment for IS typically involves anticonvulsant drugs, such as vigabatrin, topiramate, and adrenocorticotropic hormone (ACTH). These drugs are used to reduce the frequency and severity of spasms, as well as to prevent further seizures. The Infantile Spasm Drug market is a subset of the Central Nervous System Drugs market. It is a small but growing market, driven by the increasing prevalence of IS and the need for effective treatments. The market is highly competitive, with a number of companies offering various drugs for the treatment of IS. Some of the major companies in the Infantile Spasm Drug market include Pfizer, Novartis, Sanofi, GlaxoSmithKline, and Merck. These companies offer a range of drugs for the treatment of IS, including vigabatrin, topiramate, and ACTH. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.